vs
Side-by-side financial comparison of Enveric Biosciences, Inc. (ENVB) and Alaunos Therapeutics, Inc. (TCRT). Click either name above to swap in a different company.
On growth, Enveric Biosciences, Inc. posted the faster year-over-year revenue change (-11.1% vs -40.0%). Over the past eight quarters, Alaunos Therapeutics, Inc.'s revenue compounded faster (NaN% CAGR vs NaN%).
Enveric Biosciences, Inc. is a clinical-stage biotechnology company developing novel therapeutics derived from cannabinoids and related molecules. Its product pipeline addresses unmet needs in mental health disorders including anxiety, depression, and treatment-resistant conditions, as well as adverse effects linked to cancer treatment. It operates mainly in North American and European biopharmaceutical markets, partnering with research institutes to advance candidates for underserved patient groups.
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
ENVB vs TCRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $-250 | $3.0K |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 877569.2% | — |
| Net Margin | — | — |
| Revenue YoY | -11.1% | -40.0% |
| Net Profit YoY | — | -20.5% |
| EPS (diluted) | $-23.24 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $-250 | $3.0K | ||
| Q3 25 | — | $0 | ||
| Q2 25 | $-132 | $0 | ||
| Q1 25 | — | $2.0K | ||
| Q4 24 | $-225 | $5.0K | ||
| Q3 24 | $-217 | $0 | ||
| Q2 24 | $-35 | $4.0K | ||
| Q1 24 | — | $1.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-2.5M | $-1.1M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.1M | $-1.1M | ||
| Q2 24 | $-1.9M | $-1.1M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | 877569.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1908370.5% | — | ||
| Q1 25 | — | -54600.0% | ||
| Q4 24 | 1410589.3% | — | ||
| Q3 24 | 959996.3% | — | ||
| Q2 24 | 5422660.0% | -29150.0% | ||
| Q1 24 | — | -174200.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1908470.5% | — | ||
| Q1 25 | — | -53650.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | 960383.4% | — | ||
| Q2 24 | 5369697.1% | -28225.0% | ||
| Q1 24 | — | -168200.0% |
| Q4 25 | $-23.24 | — | ||
| Q3 25 | — | $-0.55 | ||
| Q2 25 | $-0.97 | $-0.63 | ||
| Q1 25 | — | $-0.67 | ||
| Q4 24 | $-172.45 | — | ||
| Q3 24 | $-43.10 | $-0.70 | ||
| Q2 24 | $-3.72 | $-0.71 | ||
| Q1 24 | — | $-1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $2.2M |
| Total Assets | $5.1M | $3.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $319.0K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $4.1M |
| Q4 25 | $4.2M | $2.2M | ||
| Q3 25 | — | $2.8M | ||
| Q2 25 | $2.2M | $3.7M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | $1.6M | $2.1M | ||
| Q3 24 | $4.0M | $2.7M | ||
| Q2 24 | $5.4M | $3.8M | ||
| Q1 24 | — | $4.8M |
| Q4 25 | $5.1M | $3.0M | ||
| Q3 25 | — | $3.7M | ||
| Q2 25 | $3.5M | $4.7M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | $3.1M | $2.8M | ||
| Q3 24 | $4.8M | $3.5M | ||
| Q2 24 | $6.1M | $4.7M | ||
| Q1 24 | — | $6.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $-2.9M |
| Free Cash FlowOCF − Capex | — | $-3.0M |
| FCF MarginFCF / Revenue | — | -98900.0% |
| Capex IntensityCapex / Revenue | — | 3266.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.8M | $-2.9M | ||
| Q3 25 | — | $-844.0K | ||
| Q2 25 | $-1.9M | $-701.0K | ||
| Q1 25 | — | $-772.0K | ||
| Q4 24 | $-1.3M | $-5.0M | ||
| Q3 24 | $-927.1K | $-781.0K | ||
| Q2 24 | $-2.9M | $-1.7M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -98900.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3266.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
